Sugi Predict

Sugi Predict / Compounds / SCHEMBL9203

SCHEMBL9203

SCHEMBL9203

NC(=O)CCCCC1CCCCC1

nearest known ligand 0.58

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ SIGMAR1 Q99720 3/20 0.54
▸ KDM5A P29375 3/20 0.51
▸ PHF8 Q9UPP1 3/20 0.51
▸ KDM2A Q9Y2K7 3/20 0.51
▸ KDM4C Q9H3R0 2/20 0.51
▸ KDM4A O75164 1/20 0.51
▸ NAAA Q02083 2/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ TARDBP Q13148 1/20 0.47
▸ CYP1A2 P05177 1/20 0.46
▸ EPHX1 P07099 1/20 0.46
▸ HPGD P15428 1/20 0.46
▸ GLA P06280 2/20 0.44
▸ ALOX5 P09917 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL931403 1.00 SIGMAR1 (0.54) SIGMAR1KDM5APHF8KDM2AKDM4C
SCHEMBL8860844 0.98 SIGMAR1 (0.57) SIGMAR1KDM5APHF8KDM2AKDM4C
SCHEMBL11010082 0.98 SIGMAR1 (0.57) SIGMAR1KDM5APHF8KDM2AKDM4C
SCHEMBL9718136 0.98 SIGMAR1 (0.57) SIGMAR1KDM5APHF8KDM2AKDM4C
SCHEMBL20408333 0.98 SIGMAR1 (0.57) SIGMAR1KDM5APHF8KDM2AKDM4C
SCHEMBL13520 0.98 SIGMAR1 (0.57) SIGMAR1KDM5APHF8KDM2AKDM4C
SCHEMBL4677733 0.98 KDM5A (0.50) SIGMAR1KDM5APHF8KDM2AKDM4C
SCHEMBL24095875 0.96 SIGMAR1 (0.54) SIGMAR1KDM5APHF8KDM2AKDM4C
SCHEMBL4537554 0.96 SIGMAR1 (0.54) SIGMAR1KDM5APHF8KDM2AKDM4C
SCHEMBL9100 0.93 SIGMAR1 (0.50) SIGMAR1KDM5APHF8KDM2AKDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110144033-A1 Proteasome Inhibitors and Methods of Using the Same CEPHALON, INC. (US) 2011-06-16 — — US claimed
US-7915236-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2011-03-29 — — US claimed
EP-1660507-B9 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-03-24 — — EP claimed
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2009-11-26 — — US claimed
EP-1660507-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2009-08-05 — — EP claimed
CN-1867572-A proteasome inhibitors and methods of use thereof CEPHALON INC (US) 2006-11-22 — — CN claimed
EP-1660507-A2 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2006-05-31 — — EP claimed
US-20050107307-A1 Proteasome inhibitors and methods of using the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-19 — — US claimed
WO-2005021558-A2 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2005-03-10 — — WO claimed
EP-1660507-B2 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME MILLENNIUM PHARM INC (US) 2017-01-04 — — EP disclosed
US-9296698-B2 Amino heteroaryl compounds as beta-secretase modulators and methods of use AMGEN INC. (US) 2016-03-29 — — US disclosed
US-9233115-B2 Proteasome inhibitors and methods of using the same MILLENNIUM PHARMACEUTICALS INC. (US) 2016-01-12 — — US disclosed
CN-101309900-B Substituted cycloalkene derivative DAIICHI SANKYO CO LTD 2015-04-22 — — CN disclosed
US-20140088042-A1 Proteasome Inhibitors And Methods Of Using The Same CEPHALON, INC. (US) 2014-03-27 — — US disclosed
US-20080114036-A1 Novel Compounds, Their Preparations And Use NOVO NORDISK A/S (DK) 2008-05-15 — — US disclosed
EP-1745002-A1 NOVEL COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2007-01-24 — — EP disclosed
WO-2005105725-A1 NOVEL COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2005-11-10 — — WO disclosed
US-20050107307-A1 Proteasome inhibitors and methods of using the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-19 — — US disclosed
US-6057371-A TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS, GASTROINTESTINAL DISORDERS, DRUG ABUSE, ANGINA, MIGRAINE, HYPERTENSION AND DEPRESSION VIRGINIA COMMONWEALTH UNIVERSITY (US) 2000-05-02 — — US disclosed
EP-0513285-A1 IMIDAZOL-2-YL DERIVATIVES OF SUBSTITUTED BICYCLIC COMPOUNDS AND PROCESS FOR THEIR PREPARATION. ERBA CARLO SPA (IT) 1992-11-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME PSMB11, PSMB5, PSMB6 SIGMAR1 4062/4885KDM5A 1680/4885PHF8 1168/4885
US-20050107307-A1 Proteasome inhibitors and methods of using the same PSMB11, PSMB5, PSMB6 SIGMAR1 4062/4885KDM5A 1680/4885PHF8 1168/4885
US-20140088042-A1 Proteasome Inhibitors And Methods Of Using The Same PSMB11, PSMB5, PSMB6 SIGMAR1 4062/4885KDM5A 1680/4885PHF8 1168/4885
US-20080114036-A1 Novel Compounds, Their Preparations And Use PPARG, PPARD, GPR119 SIGMAR1 1164/4885KDM5A 4551/4885PHF8 4433/4885
US-20110144033-A1 Proteasome Inhibitors and Methods of Using the Same PSMB11, PSMB5, PSMB6 SIGMAR1 4062/4885KDM5A 1680/4885PHF8 1168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.